MS vs Onc division which one is better??

As much as you dorks make fun of MSBU it IS the Most Profitable BU at Novartis by far. By far and out. You have to be in denial to disagree

 

I think profitable is debatable. Split profits with Mitsubishi. R&D costs above other products because costs of MS trials. Gilenya below expectations in revenues at 4 years. A lot of resources for MS drug - nurses, outside help from vendors, layers of sales/kams/sams. Oncology is probably more profitable. No doubt that Gilenya makes a profit.

Its not making fun of the MSBU - it is telling the truth and hopefully a potential new employee reads this and realizes what they are getting into.

 

The PC mentality is why MS KOLs do not think highly of Novartis.These physicians deal with Biogen, Teva, Genzyme.These companies understand these KOLs and Novartis put a PC leadership team in place thinking PC tactics would work.4 years later the failure is evident. You only launch once and it needs to be successful.

 

Doesn't really matter. Both are like PCP now.